CN1214694A - 具有抗增殖特性的肽 - Google Patents

具有抗增殖特性的肽 Download PDF

Info

Publication number
CN1214694A
CN1214694A CN97193351A CN97193351A CN1214694A CN 1214694 A CN1214694 A CN 1214694A CN 97193351 A CN97193351 A CN 97193351A CN 97193351 A CN97193351 A CN 97193351A CN 1214694 A CN1214694 A CN 1214694A
Authority
CN
China
Prior art keywords
peptide
dna
rna
growth factor
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN97193351A
Other languages
English (en)
Chinese (zh)
Inventor
拉兹文·T·拉都勒斯丘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19653445A external-priority patent/DE19653445C1/de
Application filed by Individual filed Critical Individual
Publication of CN1214694A publication Critical patent/CN1214694A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN97193351A 1996-03-26 1997-03-26 具有抗增殖特性的肽 Pending CN1214694A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19611939.1 1996-03-26
DE19611939 1996-03-26
DE19653445.3 1996-12-20
DE19653445A DE19653445C1 (de) 1996-03-26 1996-12-20 Peptide mit antineoplastischen Eigenschaften

Publications (1)

Publication Number Publication Date
CN1214694A true CN1214694A (zh) 1999-04-21

Family

ID=26024147

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97193351A Pending CN1214694A (zh) 1996-03-26 1997-03-26 具有抗增殖特性的肽

Country Status (10)

Country Link
US (1) US6660830B1 (https=)
EP (1) EP0892811B1 (https=)
JP (1) JP2001508643A (https=)
CN (1) CN1214694A (https=)
AT (1) ATE229977T1 (https=)
AU (1) AU727662B2 (https=)
BR (1) BR9711795A (https=)
CA (1) CA2251691A1 (https=)
NO (1) NO984415L (https=)
WO (1) WO1997035873A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104558200A (zh) * 2004-09-02 2015-04-29 克格诺西有限公司 改进的apo e类似物及其使用方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2400567T3 (es) 2004-04-21 2013-04-10 The University Of Chicago Inhibidores de cinasa de la cadena ligera de miosina y su uso
KR101364374B1 (ko) * 2005-03-14 2014-02-17 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 생활성 ｆｕｓ1 펩티드 및 나노입자-폴리펩티드 복합체
KR100729830B1 (ko) * 2005-03-24 2007-06-19 바이오스펙트럼 주식회사 페너트라틴을 이용하여 단백질의 세포투과를 증진시키는대장균용발현벡터
US9243035B2 (en) * 2013-11-26 2016-01-26 Nymox Corporation Peptides effective in the treatment of conditions requiring the removal or destruction of cells
US10513711B2 (en) 2014-08-13 2019-12-24 Dupont Us Holding, Llc Genetic targeting in non-conventional yeast using an RNA-guided endonuclease
CN107406838A (zh) 2014-11-06 2017-11-28 纳幕尔杜邦公司 Rna引导的内切核酸酶向细胞中的肽介导的递送
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
AU2016338785B2 (en) 2015-10-12 2022-07-14 E. I. Du Pont De Nemours And Company Protected DNA templates for gene modification and increased homologous recombination in cells and methods of use
EP3365440B1 (en) 2015-10-20 2022-09-14 Pioneer Hi-Bred International, Inc. Restoring function to a non-functional gene product via guided cas systems and methods of use
WO2017079026A1 (en) 2015-11-06 2017-05-11 E. I. Du Pont De Nemours And Company Generation of complex trait loci in soybean and methods of use
EP3699281A1 (en) 2016-03-11 2020-08-26 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
AU2017286122A1 (en) 2016-06-14 2018-11-22 Pioneer Hi-Bred International, Inc. Use of Cpf1 endonuclease for plant genome modifications
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
CA3018430A1 (en) 2016-06-20 2017-12-28 Pioneer Hi-Bred International, Inc. Novel cas systems and methods of use
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US11519009B2 (en) 2017-01-09 2022-12-06 University Of Massachusetts Complexes for gene deletion and editing
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
CN111465689B (zh) 2017-12-15 2024-07-12 丹尼斯科美国公司 Cas9变体和使用方法
KR20200124702A (ko) 2018-02-23 2020-11-03 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 신규한 cas9 오르소로그
US12365888B2 (en) 2018-12-14 2025-07-22 Pioneer Hi-Bred International, Inc. CRISPR-Cas systems for genome editing
CA3136113A1 (en) 2019-04-05 2020-10-08 Danisco Us Inc. Methods for polynucleotide integration into the genome of bacillus using dual circular recombinant dna constructs and compositions thereof
US20220177923A1 (en) 2019-04-05 2022-06-09 Danisco Us Inc Methods for integrating a donor DNA sequence into the genome of bacillus using linear recombinant DNA constructs and compositions thereof
EP4627078A1 (en) 2022-12-01 2025-10-08 Danisco US Inc. Iterative muliplex genome engineering in microbial cells using a bidirectional selection marker system
WO2024118882A1 (en) 2022-12-01 2024-06-06 Genencor International Bv Iterative multiplex genome engineering in microbial cells using a selection marker swapping system
WO2024118876A1 (en) 2022-12-01 2024-06-06 Genencor International Bv Iterative multiplex genome engineering in microbial cells using a recombinant self-excisable selection marker system
CN121152874A (zh) 2023-03-20 2025-12-16 先锋国际良种公司 具有改变的PAM识别的Cas多肽

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851991A (en) * 1987-08-31 1998-12-22 The Regents Of The University Of California Therapeutic use of the retinoblastoma susceptibility gene product
WO1989006703A1 (en) * 1988-01-21 1989-07-27 Massachusetts Eye And Ear Infirmary Diagnosis of retinoblastoma
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
IL106760A (en) * 1992-08-25 1999-12-31 Miles Inc Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus
DE4237129A1 (de) * 1992-11-03 1994-05-05 Radulescu Razvan Tudor Dr Med Anwendung der Komplementärpeptid-Theorie in der Onkologie/Kartiologie: 1. VPH = NH¶2¶-len alphaN-Me-Phe Tyr Lys alphaN-Me-Lys Val D-Tyr-COOH 2. Kalziumantagonist auf der Basis eines Komplementärpeptides zur Calmodulinbindungsstelle 3.hSNI¶B¶¶1¶¶6¶¶-¶¶2¶¶1¶[3'->5'] = NH¶2¶-Len Pro Thr His Asp Ala-COOH
US5625031A (en) * 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
EP0685493A1 (en) * 1994-06-01 1995-12-06 CANJI, Inc. Tumor suppressor fusion proteins
WO1995034647A1 (en) * 1994-06-13 1995-12-21 Vanderbilt University Compositions for and methods of enhancing delivery of nucleic acids to cells
US5573925A (en) * 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains
DE19526174C2 (de) * 1995-07-18 1998-02-26 Friedhelm Prof Dr Herrmann Mittel gegen Tumorwachstum

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104558200A (zh) * 2004-09-02 2015-04-29 克格诺西有限公司 改进的apo e类似物及其使用方法
CN104558200B (zh) * 2004-09-02 2021-11-16 康石医药科技（上海）有限公司 改进的apo e类似物及其使用方法

Also Published As

Publication number Publication date
WO1997035873A3 (de) 1997-12-31
JP2001508643A (ja) 2001-07-03
EP0892811A2 (de) 1999-01-27
US6660830B1 (en) 2003-12-09
ATE229977T1 (de) 2003-01-15
EP0892811B1 (de) 2002-12-18
WO1997035873A2 (de) 1997-10-02
AU727662B2 (en) 2000-12-21
AU2633497A (en) 1997-10-17
BR9711795A (pt) 2000-06-06
NO984415D0 (no) 1998-09-22
NO984415L (no) 1998-09-22
CA2251691A1 (en) 1997-10-02

Similar Documents

Publication Publication Date Title
CN1214694A (zh) 具有抗增殖特性的肽
JP7179241B1 (ja) 環状ペプチド化合物の医薬用途
TWI404726B (zh) 腫瘤轉移抑制素衍生物及其用途
US8614177B2 (en) Peptides
CN1143372A (zh) 血细胞生成成熟因子
JPS62174026A (ja) 白血球減少症治療剤
AU733964B2 (en) Novel flt-3 receptor agonists
CN113336829B (zh) 靶向anp32a抗白血病的小分子肽及其制备方法和应用
WO1998007858A1 (en) HUMAN POLYHOMEOTIC 1(hphl) ACTS AS A TUMOR SUPPRESSOR
CN111499723B (zh) 一种嵌合抗原受体及其应用
AU2017235382B2 (en) Peptides with anti-cancer activity
JP6872713B2 (ja) 腫瘍細胞の放射線感受性を増大させる合成ペプチド及びその利用
JPS58206545A (ja) 免疫調節ペプチド
JPH04505019A (ja) ガンマインターフェロンのポリペプチド性阻害剤
JPH04507237A (ja) タフトシン類縁体
KR20240161853A (ko) 신규한 화합물 및 이의 간암 치료 용도
JP4831410B2 (ja) 抗ウイルス性ペプチドおよび抗ウイルス剤
KR20120095063A (ko) ＩＬ-27로 유도된 ｐ53을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
US20050137129A1 (en) Novel compounds
JP2002510312A (ja) 分泌蛋白
WO2012124641A1 (ja) 抗癌剤の活性増強剤
CN112891513A (zh) 一种阳离子多肽-热休克蛋白-miRNA基因复合物及其制备方法和应用
US7893031B2 (en) Neuronal differentiation inhibitor peptide and use thereof
CN1476479A (zh) 人原癌基因及其编码的蛋白质
CN116621938A (zh) 电压门控钾通道Kv10.1结合肽及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication